Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
24/10/2026
Intel fell over 2% in pre-market trading and is now at $85.725.
Latest
15 m ago
Daqin Railway completes autumn centralized maintenance 2 days ahead of schedule; average daily transport volume to rebound above 1.2 million tons.
17 m ago
Yemen's Transport Minister said the Houthis have attacked Aden Airport for the fourth time; air traffic at the airport is normal, city life is normal, and both the airport and the port are operating as usual.
35 m ago
Study data presented at a medical conference on Saturday showed that Amgen's drug Imdelltra, when used in combination with AstraZeneca's immunotherapy Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, outperforming Imfinzi alone. For this aggressive and difficult-to-treat cancer, Imfinzi is currently the standard post-chemotherapy treatment option for patients whose disease has not worsened after initial chemotherapy. The study showed that patients in the combination group had a median survival of 21.1 months, compared with 12.7 months in the monotherapy group. Amgen Chief Medical Officer Paul Burton said that the earlier Imdelltra is used, the greater the clinical benefit patients receive. He said the results are unprecedented in advancing the treatment of extensive-stage small cell lung cancer.
37 m ago
Amgen drug combined with immunotherapy extended patient survival in lung cancer clinical trial.
41 m ago
Navigational warning: Rocket launch in certain waters of the South China Sea, entry prohibited
See all latest
